Skip to Content

CSL Ltd ADR CSLLY

Morningstar Rating
$92.71 +0.32 (0.35%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CSLLY is trading at a 2% discount.
Price
$92.58
Fair Value
$13.17
Uncertainty
Low
1-Star Price
$578.33
5-Star Price
$61.83
Economic Moat
Hscpf
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CSLLY is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$92.39
Day Range
$90.9894.33
52-Week Range
$71.51105.11
Bid/Ask
$93.39 / $94.48
Market Cap
$89.58 Bil
Volume/Avg
38,586 / 53,133

Key Statistics

Price/Earnings (Normalized)
28.36
Price/Sales
6.31
Dividend Yield (Trailing)
1.27%
Dividend Yield (Forward)
1.27%
Total Yield
1.27%

Company Profile

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world’s second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Growth
Total Number of Employees
30,000

Competitors

Valuation

Metric
CSLLY
GRF.P
4502
Price/Earnings (Normalized)
28.3637.2314.47
Price/Book Value
5.130.871.01
Price/Sales
6.310.821.65
Price/Cash Flow
32.918.57
Price/Earnings
CSLLY
GRF.P
4502

Financial Strength

Metric
CSLLY
GRF.P
4502
Quick Ratio
0.950.720.46
Current Ratio
2.152.481.06
Interest Coverage
7.211.281.93
Quick Ratio
CSLLY
GRF.P
4502

Profitability

Metric
CSLLY
GRF.P
4502
Return on Assets (Normalized)
7.37%1.17%2.86%
Return on Equity (Normalized)
16.50%4.22%6.13%
Return on Invested Capital (Normalized)
10.05%3.28%4.78%
Return on Assets
CSLLY
GRF.P
4502
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRRfht$537.7 Bil
VRTX
Vertex Pharmaceuticals IncZjzldnf$108.4 Bil
REGN
Regeneron Pharmaceuticals IncFknjz$104.6 Bil
MRNA
Moderna IncBzfrn$33.4 Bil
ARGX
argenx SE ADRDfsb$23.7 Bil
BNTX
BioNTech SE ADRXhbkz$22.0 Bil
ALNY
Alnylam Pharmaceuticals IncCxqlxf$19.5 Bil
BMRN
Biomarin Pharmaceutical IncGfxcbw$16.7 Bil
RPRX
Royalty Pharma PLC Class AVnpbyt$14.0 Bil
INCY
Incyte CorpJtsynz$13.5 Bil

Sponsor Center